CERRITOS, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) has announced the appointment of Jeremy Castle, MBA, as Chief Operations Officer, effective September 5, 2023. In this role, Mr. Castle leads enterprise field and central operations, pharmacy, real estate, and practice integration, playing a key role in driving TOI’s success as a public company.
Mr. Castle joins TOI with over 15 years of oncology industry experience, and has a track record of driving growth and profitability for multi-state physician groups. He has had other senior leadership positions, including Mr. Castle having previously served as the Chief Operating Officer for United Urology Group and Executive Director for The US Oncology Network.
“We are thrilled to welcome Jeremy to TOI as our Chief Operations Officer,” shared Chief Executive Officer, Dr. Daniel Virnich. “He brings significant oncology operations experience, as well as deep experience with value-based care, and I am confident that his expertise in Oncology will greatly benefit TOI as we seek to rapidly accelerate our growth.”
“TOI is entering an exciting chapter in its history, and I feel energized to join this team of progressive and passionate leaders and clinicians dedicated to changing oncology for the better,” said Castle. “As Chief Operations Officer, I will have the opportunity to serve TOI’s patients, teammates, community, and shareholders. I look forward to contributing to the company’s continued success.”
About TOI
Founded in 2007, The Oncology Institute, Inc. (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 100+ employed clinicians and more than 800 teammates in over 65 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$2.16 |
Daily Change: | 0.22 11.34 |
Daily Volume: | 932,229 |
Market Cap: | US$163.210M |
March 24, 2025 November 13, 2024 November 11, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load